Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-501 (CNTF) Implants for Retinitis Pigmentosa
NCT00447980Phase 2Completed
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- Jan 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of encorafenib in retinitis pigmentosa (RP), Usher syndrome type 2 (USH2), Usher syndrome type 3 and 1 more (2 arms), sponsored by Neurotech Pharmaceuticals, Inc. Primary endpoint: Change in Humphrey Visual Fields - Total Sensitivity at 12 months. Started Jan 2007; status: completed.
02
Drugs
encorafenib
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2 (USH2)Usher syndrome type 3choroideremia
Beyond the preview
Go deeper on NCT00447980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447980.